Tag - NOVN

Markets

Cantor starts Novan at OW; PT $30

Cantor Fitzgerald initiated coverage of Novan (NASDAQ:NOVN) with an “overweight” rating and $30 price target. The stock closed at $9.10 on July 8. Novan is a clinical-stage biotechnology company focused on leveraging...

July 9, 2021

Developments

Novan completes enrollment in pivotal Phase 3 molluscum contagiosum trial

Novan (NASDAQ:NOVN) has completed patient enrollment in its Phase 3 pivotal trial of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum. Molluscum contagiosum is a viral skin infection that...

August 14, 2019

Tag - NOVN

Cantor starts Novan at OW; PT $30

Novan completes enrollment in pivotal Phase 3 molluscum contagiosum trial

General

More